Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Unknown × vistusertib × Clear all

Phase

Phase 1/2 2 Phase 2 1

Status

Terminated 4 Completed 3 Active not recruiting 3 Withdrawn 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cisplatin 238 Carboplatin 162 Oxaliplatin 159 Docetaxel 155 Capecitabine 155 apatinib 148 Paclitaxel 141 Gemcitabine 135 Radiotherapy 130 Bevacizumab 128 Fluorouracil 125 camrelizumab 124 Cyclophosphamide 114 Irinotecan 107 Etoposide 91 Drug Therapy 89 sintilimab 87 S 1 (combination) 73 Leucovorin 72 anlotinib 71 Doxorubicin 70 pembrolizumab 68 tislelizumab 65 toripalimab 64 Pemetrexed 64 Dexamethasone 61 Rituximab 59 Neoadjuvant Therapy 58 Trastuzumab 57 Cetuximab 57

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡